SEC Form 4 · accession 0001140361-15-012556
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Henry J Fuchs
Officer — EVP, Chief Medical Officer
Period of report
Mar 16, 2015
Accepted (ET)
Mar 18, 2015 · 7:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 16, 2015 | M | 34,155 | $21.51 | A | 124,105 | D | |
| Common StockF1 | Mar 16, 2015 | M | 5,845 | $21.51 | A | 129,950 | D | |
| Common StockF1,F2 | Mar 16, 2015 | S | 41,315 | $123.5669 | D | 88,635 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Common StockF1,F4,F3 | $21.51 | Mar 16, 2015 | M | 34,155 | D | Nov 12, 2010 | May 11, 2020 | Common Stock | 34,155 | 0 | D |
| Stock Option (right to buy) Common StockF1,F4,F3 | $21.51 | Mar 16, 2015 | M | 5,845 | D | Nov 12, 2010 | May 11, 2020 | Common Stock | 5,845 | 2,000 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on March 2, 2015.
- F2The price in column 4 is a weighted average price. The price actually received ranged from $121.49 to $124.94. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.
- F3Option grant vests 6/48ths on November 12, 2010, and 1/48th on the 10th day of every month thereafter.
- F4Reflect the number of stock options that remain outstanding from this specific stock option grant following the reported transaction.